Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Nanfeng Fan"'
Publikováno v:
Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Background Cancer cells can resist chemotherapy through various mechanisms, diminishing treatment outcomes. Research had indicated that combining miR-122 with doxorubicin (DOX) can improve hepatocellular carcinoma (HCC) therapy. Results To e
Externí odkaz:
https://doaj.org/article/c3c8e35e79c34341896f5e93527296b6
Autor:
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104966- (2024)
Summary: Background: Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. Methods: This is an open-label,
Externí odkaz:
https://doaj.org/article/51a30c01a2774b8782efcb9593d768c2
Autor:
Zhi Peng, Tianshu Liu, Jia Wei, Airong Wang, Yifu He, Liuzhong Yang, Xizhi Zhang, Nanfeng Fan, Suxia Luo, Zhen Li, Kangsheng Gu, Jianwei Lu, Jianming Xu, Qingxia Fan, Ruihua Xu, Liangming Zhang, Enxiao Li, Yuping Sun, Guohua Yu, Chunmei Bai, Yong Liu, Jiangzheng Zeng, Jieer Ying, Xinjun Liang, Nong Xu, Chao Gao, Yongqian Shu, Dong Ma, Guanghai Dai, Shengmian Li, Ting Deng, Yuehong Cui, Jianmin Fang, Yi Ba, Lin Shen
Publikováno v:
Cancer Communications, Vol 41, Iss 11, Pp 1173-1182 (2021)
Abstract Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemist
Externí odkaz:
https://doaj.org/article/84d42b69d5e24a3c9b4936b33833bf96
Autor:
Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cance
Externí odkaz:
https://doaj.org/article/f06362cd43f14da3aea28fa6948f7e44
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
In the latest literatures, ferroptosis caused by T cells in cancerous cells provided new insights of improving curative effect of the PD-1/PD-L1 antibody. The microenvironment on which tumor cells develop and survive was also emphasized as its crucia
Externí odkaz:
https://doaj.org/article/7a08f25df9bc417eb2883ab5a90f092c
Publikováno v:
Frontiers in genetics. 13
In the latest literatures, ferroptosis caused by T cells in cancerous cells provided new insights of improving curative effect of the PD-1/PD-L1 antibody. The microenvironment on which tumor cells develop and survive was also emphasized as its crucia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66378139015af07ff266af4214c291fc
https://pubmed.ncbi.nlm.nih.gov/35350245
https://pubmed.ncbi.nlm.nih.gov/35350245
Autor:
Chao Gao, Yuehong Cui, Jianmin Fang, Jia Wei, Guohua Yu, Dong Ma, Yuping Sun, Jieer Ying, Yi Ba, Yongqian Shu, Suxia Luo, Shengmian Li, Yong Liu, Liangming Zhang, Zhen Li, Airong Wang, Guanghai Dai, Lin Shen, Liuzhong Yang, Chunmei Bai, Tianshu Liu, Xinjun Liang, Jiangzheng Zeng, Kangsheng Gu, Rui-Hua Xu, Jianwei Lu, X. Zhang, Ting Deng, Jianming Xu, Yifu He, Nong Xu, Enxiao Li, Nanfeng Fan, Q. Fan, Zhi Peng
Publikováno v:
Cancer Communications
Cancer Communications, Vol 41, Iss 11, Pp 1173-1182 (2021)
Cancer Communications, Vol 41, Iss 11, Pp 1173-1182 (2021)
Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d466c291980276380143f0464fe645b
https://pubmed.ncbi.nlm.nih.gov/34665942
https://pubmed.ncbi.nlm.nih.gov/34665942
Autor:
Jie Liu, Rongbo Lin, Yigui Chen, Nanfeng Fan, Jiaqing Yu, Min Zhou, Shen Zhao, Feng Huang, Hui Li
Publikováno v:
Ann Transl Med
Background Apatinib combined with chemotherapy might be effective and safe for the management of advanced gastric cancer, but the available data are limited. To investigate the efficacy and safety of apatinib in combination with paclitaxel (PTX) alon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59c2476ef69c4b0970fe87b631c6bbcd
https://pubmed.ncbi.nlm.nih.gov/33178765
https://pubmed.ncbi.nlm.nih.gov/33178765
Publikováno v:
Experimental Cell Research. 409:112892
Carnitine palmitoyltransferase 2 (CPT2) has been demonstrated to act as a tumor promotor or suppressor in different types of cancers. However, little is known about the effect of CPT2 on colorectal cancer (CRC). In the present study, we analyzed CPT2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25911b1a30175b6b5b50a18e13bfd3dd
https://doi.org/10.1016/j.yexcr.2021.112892
https://doi.org/10.1016/j.yexcr.2021.112892
Autor:
Rongbo Lin, Jie Liu, Hui Li, Shen Zhao, Wujin Chen, Xiaofeng Li, Wenzheng Fang, Peicheng Lin, Yigui Chen, Nanfeng Fan, Jinfeng Zhu
Publikováno v:
Journal of Clinical Oncology. 39:4041-4041
4041 Background: Progression-free (PFS) and overall (OS) survival for SYLT/FNF 004 were previously reported in ASCO and ASCO-GI 2019. At that time, PFS was statistically significantly improved with ivPOF or ipPOF compared to mFOLFOX6 as first-line tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c38c556141016055fcc5bcd99b88983
https://doi.org/10.1200/jco.2021.39.15_suppl.4041
https://doi.org/10.1200/jco.2021.39.15_suppl.4041